Docetaxel rechallenge after an initial good response in patients with metastatic castration‐resistant prostate cancer

Abstract

Docetaxel rechallenge is a management option for responders to docetaxel with a PFI of >6 months, but did not prolong survival. Potential benefits should be weighed against the risk of cumulative toxicity.